hypoglycemic agents

Preferred Label : hypoglycemic agents;

MeSH definition : Substances which lower blood glucose levels.;

MeSH synonym : agents, hypoglycemic; hypoglycemics; hypoglycemic drugs; drugs, hypoglycemic; antihyperglycemic agents; agents, antihyperglycemic; antihyperglycemics; Hypoglycemic Agent; Agent, Hypoglycemic; Antihyperglycemic Agent; Agent, Antihyperglycemic; Hypoglycemic; Antihyperglycemic; Hypoglycemic Drug; Drug, Hypoglycemic;

Related MeSH term : hypoglycemic effect; antidiabetics; Effect, Hypoglycemic; Hypoglycemic Effects; Effects, Hypoglycemic; Antidiabetic Drugs; Drugs, Antidiabetic; Antidiabetic Agents; Agents, Antidiabetic; Antidiabetic Drug; Drug, Antidiabetic; Antidiabetic Agent; Agent, Antidiabetic; Antidiabetic;

MeSH annotation : note entry term HYPOGLYCEMIC EFFECT: use only for the hypoglycemic effect of a chemical substance;

Wikipedia link : https://en.wikipedia.org/wiki/Hypoglycemic agents;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D007004;

UMLS CUI

C0020616;

ATC code(s)
- acarbose [ATC Code]
- acetohexamide [ATC Code]
- benfluorex [ATC Code]
- biguanides [ATC Code]
- blood glucose lowering drugs, excl. insulins [ATC Code]
- buformin [ATC Code]
- carbutamide [ATC Code]
- chlorpropamide [ATC Code]
- combinations of oral blood glucose lowering drugs [ATC Code]
- drugs used in diabetes [ATC Code]
- glibenclamide [ATC Code]
- glibornuride [ATC Code]
- gliclazide [ATC Code]
- glipizide [ATC Code]
- gliquidone [ATC Code]
- glisoxepide [ATC Code]
- glymidine [ATC Code]
- metahexamide [ATC Code]
- miglitol [ATC Code]
- mitiglinide [ATC Code]
- nateglinide [ATC Code]
- phenformin [ATC Code]
- pioglitazone [ATC Code]
- pramlintide [ATC Code]
- repaglinide [ATC Code]
- rosiglitazone [ATC Code]
- sulfonylureas [ATC Code]
- tolazamide [ATC Code]
- tolbutamide [ATC Code]
- tolrestat [ATC Code]
- troglitazone [ATC Code]
- voglibose [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Anti-hyperglycemics [LOINC component]
- Antidiabetic [ICHI extension code]
- Antidiabetic agent (substance) [Inactive SNOMED CT concept]
- Drug-induced hypoglycaemia [ICD-11 More detail]
- Drug-induced hypoglycemia (disorder) [SNOMED CT concept]
- Hypoglycemic agent (product) [SNOMED CT concept]
- Hypoglycemics.oral [LOINC component]
- diabetes medicines [MedlinePlus Topic]
- drugs for treatment of hypoglycemia [ATC Code]
- hypoglycemic agent [Artificial nutrition thesaurus concept]
- hypoglycemic drug, nos [SNOMED Notion]
- other drugs used in diabetes [ATC Code]
Currated CISMeF NLP mapping
- Anti-diabetic Agent [NCIt concept]
- Antidiabetic [ICD-11 Extension code]
- Hypoglycemic agent (substance) [Inactive SNOMED CT concept]
- drugs used in diabetes [ATC Code]
Indexing information
- (2R,3R,4S,5S,6R)-2-(5-chloro-4-(4-ethylbenzyl)thiophen-2-yl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol [MeSH Supplementary Concept]
- (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol [MeSH Supplementary Concept]
- (6-((4'-(3,4-dihydroxybutoxy)-2,2',6'-trimethyl(1,1'-biphenyl)-3-yl)methoxy)-3H-spiro(1-benzofuran-2,1'-cyclopropan)-3-yl)acetic acid [MeSH Supplementary Concept]
- (S)-4'-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid [MeSH Supplementary Concept]
- (S)-4'-((5-(1-(4-bromophenyl)ethylcarbamoyl)-2,3-dimethyl-1H-indol-1-yl)methyl)biphenyl-2-carboxylic acid [MeSH Supplementary Concept]
- 1,1,1-trifluoro-2-(4-(2-((3-methylmorpholino)methyl)-4-(thiophen-2-ylsulfonyl)piperazin-1-yl)phenyl)propan-2-ol [MeSH Supplementary Concept]
- 1-(((3-hydroxy-1-adamantyl)amino)acetyl)-2-cyanopyrrolidine [MeSH Supplementary Concept]
- 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine, monohydrochloride [MeSH Supplementary Concept]
- 2-((3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenyl-1,2-dihydroisoquinolin-6-yl)oxy)acetamide [MeSH Supplementary Concept]
- 2-(4-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol [MeSH Supplementary Concept]
- 2-O-lactoylborapetoside B [MeSH Supplementary Concept]
- 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol [MeSH Supplementary Concept]
- 3-(1,1'-biphenyl)-4-yl-N,N-dimethyl-1-(3-(trifluoromethyl)phenyl)-1H-pyrazole-4-acetamide [MeSH Supplementary Concept]
- 5-(2-(1H-imidazol-1-yl)ethylthio)-3-(benzyloxy)-N-(4-isopropylthiazol-2-yl)pyridin-2-amine [MeSH Supplementary Concept]
- 6'-O-lactoylborapetoside B [MeSH Supplementary Concept]
- 6-chloro-6-deoxy-1,2,3,4-tetra-O-galloylglucopyranose [MeSH Supplementary Concept]
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [MeSH Supplementary Concept]
- AS1669058 [MeSH Supplementary Concept]
- MAC-ST-001 [MeSH Supplementary Concept]
- N-(4-(1-(3-(2-fluoro-5-trifluoromethylphenyl)-5-(6-methoxynaphth-2-yl)-1H-pyrazol-1-yl)ethyl)benzoyl)-beta-alanine [MeSH Supplementary Concept]
- SCH 900948 [MeSH Supplementary Concept]
- ZLN005 [MeSH Supplementary Concept]
- ZLN024 [MeSH Supplementary Concept]
- bacosine [MeSH Supplementary Concept]
- balaglitazone [MeSH Supplementary Concept]
- borapetoside A [MeSH Supplementary Concept]
- borapetoside C [MeSH Supplementary Concept]
- caffeic acid phenethyl amide [MeSH Supplementary Concept]
- carboxyformin [MeSH Supplementary Concept]
- cerasee tea [MeSH Supplementary Concept]
- cogent db [MeSH Supplementary Concept]
- cyclic des-acyl ghrelin (6-13) [MeSH Supplementary Concept]
- di(2-selenopyridine-N-oxidato)zinc(II) [MeSH Supplementary Concept]
- erinidine [MeSH Supplementary Concept]
- jentadueto [MeSH Supplementary Concept]
- polymatin A [MeSH Supplementary Concept]
- pterosin A [MeSH Supplementary Concept]
- ratanhiaphenol III [MeSH Supplementary Concept]
- sanguis draxonis [MeSH Supplementary Concept]
- tangzhiqing [MeSH Supplementary Concept]
- urs-12-en-3-ol-28-oic acid 3-glucopyranosyl-4'-octadecanoate [MeSH Supplementary Concept]
MedlinePlus topic(s)
- diabetes medicines [MedlinePlus Topic]
Metaterm(s)
- endocrinology [CISMeF Metaterm]
Record concept(s)
- antidiabetics [MeSH concept]
- hypoglycemic agents [MeSH concept]
- hypoglycemic effect [MeSH concept]
See also (suggested by CISMeF)
- diabetes mellitus [MeSH Descriptor]
- hypoglycemia [MeSH Descriptor]
See also inter- (CISMeF)
- Medicinal product acting as antidiabetic agent (product) [SNOMED CT concept]
- oral antidiabetics [CISMeF Querying Strategy]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 2,4-thiazolidinedione [MeSH Supplementary Concept]
- 2-bromopalmitate [MeSH Supplementary Concept]
- 2-tetradecylglycidic acid [MeSH Supplementary Concept]
- 5,7-dihydroxy-6,8-dimethyl-4'-methoxyflavone [MeSH Supplementary Concept]
- 8-(2-aminophenyl)-3-butyl-1,6,7-trimethyl-1H-imidazo(2,1-f)purine-2,4(3H,8H)-dione [MeSH Supplementary Concept]
- 8-(2-hydroxypropan-2-yl)-5-hydroxy-7-methoxy-6-methyl-4'-methoxyflavone [MeSH Supplementary Concept]
- 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid [MeSH Supplementary Concept]
- AICA ribonucleotide [MeSH Supplementary Concept]
- BRL 26830A [MeSH Supplementary Concept]
- Exenatide [MeSH Descriptor]
- Insulin Detemir [MeSH Descriptor]
- Insulin Glargine [MeSH Descriptor]
- Isophane Insulin, Human [MeSH Descriptor]
- Liraglutide [MeSH Descriptor]
- MK-2640 [MeSH Supplementary Concept]
- MR1704 [MeSH Supplementary Concept]
- MYL-1501D [MeSH Supplementary Concept]
- Nateglinide [MeSH Descriptor]
- PAZ320 [MeSH Supplementary Concept]
- Pioglitazone [MeSH Descriptor]
- Rosiglitazone [MeSH Descriptor]
- S009-0629 [MeSH Supplementary Concept]
- Topiramate [MeSH Descriptor]
- Troglitazone [MeSH Descriptor]
- Xultophy [MeSH Supplementary Concept]
- acetohexamide [MeSH Descriptor]
- allicin [MeSH Supplementary Concept]
- alliin [MeSH Supplementary Concept]
- bexagliflozin [MeSH Supplementary Concept]
- biguanides [MeSH Descriptor]
- biphasic insulins [MeSH Descriptor]
- buformin [MeSH Descriptor]
- butoxamine [MeSH Descriptor]
- carbutamide [MeSH Descriptor]
- chlorpropamide [MeSH Descriptor]
- ciglitazone [MeSH Supplementary Concept]
- copper bis(3,5-diisopropylsalicylate) [MeSH Supplementary Concept]
- diphenyleneiodonium [MeSH Supplementary Concept]
- disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate [MeSH Supplementary Concept]
- dulaglutide [MeSH Supplementary Concept]
- efpeglenatide [MeSH Supplementary Concept]
- emeriamine [MeSH Supplementary Concept]
- englitazone [MeSH Supplementary Concept]
- ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate [MeSH Supplementary Concept]
- etomoxir [MeSH Supplementary Concept]
- fenugreek seed meal [MeSH Supplementary Concept]
- firuglipel [MeSH Supplementary Concept]
- glibornuride [MeSH Supplementary Concept]
- gliclazide [MeSH Descriptor]
- glimepiride [MeSH Supplementary Concept]
- glipizide [MeSH Descriptor]
- gliquidone [MeSH Supplementary Concept]
- glucuronyl glucosamine glycan sulfate [MeSH Supplementary Concept]
- glyburide [MeSH Descriptor]
- gusperimus [MeSH Supplementary Concept]
- inositol phosphate glycan [MeSH Supplementary Concept]
- insulin [MeSH Descriptor]
- insulin aspart [MeSH Descriptor]
- insulin aspart, insulin aspart protamine drug combination 30:70 [MeSH Supplementary Concept]
- insulin degludec, insulin aspart drug combination [MeSH Supplementary Concept]
- insulin glulisine [MeSH Supplementary Concept]
- insulin lispro [MeSH Descriptor]
- insulin, Short-Acting [MeSH Descriptor]
- insulin, globin zinc [MeSH Supplementary Concept]
- insulin, isophane [MeSH Descriptor]
- insulin, lente [MeSH Descriptor]
- insulin, long-acting [MeSH Descriptor]
- insulin, neutral [MeSH Supplementary Concept]
- insulin, pork; isophane insulin, pork drug combination 30:70 [MeSH Supplementary Concept]
- insulin, protamine zinc, beef-pork [MeSH Supplementary Concept]
- insulin, regular, beef-pork [MeSH Supplementary Concept]
- insulin, regular, pork [MeSH Descriptor]
- insulin, ultralente [MeSH Descriptor]
- isophane insulin, beef [MeSH Supplementary Concept]
- isophane insulin, beef-pork [MeSH Supplementary Concept]
- isophane insulin, insulin lispro drug combination 50:50 [MeSH Supplementary Concept]
- isophane insulin, pork [MeSH Supplementary Concept]
- lixisenatide [MeSH Supplementary Concept]
- meglitinide [MeSH Supplementary Concept]
- metformin [MeSH Descriptor]
- methyl 2-tetradecylglycidate [MeSH Supplementary Concept]
- midaglizole [MeSH Supplementary Concept]
- mitiglinide [MeSH Supplementary Concept]
- peroxovanadate [MeSH Supplementary Concept]
- phenformin [MeSH Descriptor]
- phenyl biguanide [MeSH Supplementary Concept]
- ponalrestat [MeSH Supplementary Concept]
- pramlintide [MeSH Supplementary Concept]
- repaglinide [MeSH Supplementary Concept]
- tirzepatide [MeSH Supplementary Concept]
- tolazamide [MeSH Descriptor]
- tolbutamide [MeSH Descriptor]
- vanadyl sulfate [MeSH Supplementary Concept]
- velagliflozin [MeSH Supplementary Concept]
- volagidemab [MeSH Supplementary Concept]
- zopolrestat [MeSH Supplementary Concept]
UMLS correspondences (same concept)
- Anti-hyperglycemics [LOINC component]
- Hypoglycemic agent (product) [SNOMED CT concept]
- Hypoglycemic agent (substance) [Inactive SNOMED CT concept]
- diabetes medicines [MedlinePlus Topic]
- hypoglycemic drug, nos [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients